Poster-Disease-modifying Therapy
October 25, 2021
Psoriasis in Multiple Sclerosis Patients Treated with Disease Modifying Therapies
Background: Psoriasis may be more common in people living with multiple sclerosis (PwMS) than in the general population. Some pathways...
Poster-Disease-modifying Therapy
October 25, 2021
Dual Mode of Action of Siponimod in Secondary Progressive Multiple Sclerosis: A Hypothesis Based on the Relevance of Pharmacological Properties
Background: Siponimod, a potent and selective sphingosine 1-phosphate (S1P1,5) receptor modulator, is the first oral disease-modifying...
Poster-Disease-modifying Therapy
October 25, 2021
Post-Approval Safety of Subcutaneous Interferon ?-1a in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections
Background: Subcutaneous interferon ?-1a (sc IFN ?-1a) is a well-established disease-modifying therapy for relapsing multiple sclerosis...
Poster-Disease-modifying Therapy
October 25, 2021
Opportunities and Pitfalls in the Assessment of Brain Atrophy in Dimethyl Fumarate-Treated Relapsing Multiple Sclerosis Patients Using Real-World Data
Background: The majority of real-world data (RWD) on disease-modifying treatments (DMTs) for multiple sclerosis (MS) is based on clinical...
Poster-Disease-modifying Therapy
October 25, 2021
Alopecia in Multiple Scleoris Patients Treated with Disease Modifying Therapies
Background: There is limited literature about the frequency of alopecia in people with multiple sclerosis (MS) treated with disease...
Poster-Disease-modifying Therapy
October 25, 2021
Real-World Safety and Effectiveness of Delayed-Release Dimethyl Fumarate in Relapsing Multiple Sclerosis Patients: Interim Results from Esteem
Background: Dimethyl fumarate (DMF) demonstrated strong efficacy and a favorable benefitrisk profile in patients with relapsing-remitting...
Poster-Disease-modifying Therapy
October 25, 2021
Incidence and Severity of Natalizumab Infusion-Related Reactions during Infusion and Postinfusion Observation
Background: Natalizumab, an efficacious treatment for relapsing forms of multiple sclerosis, has an approved dosing of 300 mg infused...
Poster-Disease-modifying Therapy
October 25, 2021
Natalizumab: Management and Safety during the COVID-19 Pandemic
Background: MS patients treated with monoclonal antibodies have an increased risk of infections. Natalizumab (NTZ) is a monoclonal antibody...
Poster-Disease-modifying Therapy
October 25, 2021
Characteristics and Outcomes By Employment and Education Status for Patients Treated with Peginterferon Beta-1a or Intramuscular Interferon Beta-1a
Background: Although socioeconomic disparities that lead to differences in multiple sclerosis (MS) outcomes have been identified, specific...
Poster-Disease-modifying Therapy
October 25, 2021
Adherence and Persistence to Injectable Disease-Modifying Therapies Among Patients with Multiple Sclerosis Enrolled in US Commercial Plans
Background: In patients with multiple sclerosis (MS), adherence and persistence to disease-modifying therapies (DMTs) are important to...